Year,SDG Series,Reference area,Value
2007,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),,94.1
2008,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),,95.3
2009,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),,95.4
2010,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),,96.5
2011,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),,95.1
2012,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),,96.2
2013,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),,96.9
2014,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),,95.8
2015,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),,96.6
2016,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),,96.1
2017,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),,93.4
2018,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),,94.5
2019,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),,94.351083
2020,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),,88.157251
2021,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),,888.0
2007,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,93.4
2008,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,96.8
2009,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,95.4
2010,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,96.8
2011,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,96.7
2012,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,98.3
2013,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,97.7
2014,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,98.9
2015,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,98.6
2016,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,98.1
2017,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,96.7
2018,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,96.6
2019,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,98.322619
2020,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,91.684706
2021,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,869.0
2007,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,93.6
2008,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,95.6
2009,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,95.9
2010,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,95.9
2011,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,94.2
2012,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,95.9
2013,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,97.8
2014,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,94.8
2015,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,96.1
2016,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,95.8
2017,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,93.8
2018,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,96.1
2019,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,90.174029
2020,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,87.415504
2021,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,897.0
2007,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,93.9
2008,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,95.2
2009,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,95.3
2010,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,97.2
2011,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,93.6
2012,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,96.9
2013,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,97.3
2014,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,91.3
2015,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,98.0
2016,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,95.9
2017,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,96.1
2018,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,95.0
2019,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,94.575714
2020,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,87.604354
2021,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,958.0
2007,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,94.4
2008,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,95.2
2009,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,95.3
2010,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,96.8
2011,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,95.5
2012,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,97.4
2013,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,98.0
2014,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,97.6
2015,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,97.2
2016,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,96.8
2017,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,97.0
2018,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,94.8
2019,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,97.59292
2020,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,90.958705
2021,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,965.0
2007,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,94.4
2008,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,94.5
2009,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,95.1
2010,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,95.5
2011,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,93.6
2012,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,93.0
2013,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,96.2
2014,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,98.3
2015,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,97.1
2016,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,98.5
2017,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,96.6
2018,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,95.8
2019,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,99.33564
2020,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,95.543628
2021,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,903.0
2007,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,94.0
2008,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,94.8
2009,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,94.6
2010,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,96.8
2011,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,95.3
2012,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,96.0
2013,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,96.2
2014,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,93.4
2015,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,96.8
2016,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,95.2
2017,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,93.1
2018,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,95.3
2019,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,92.698706
2020,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,94.171956
2021,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,907.0
2007,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,94.0
2008,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,95.5
2009,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,95.5
2010,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,96.3
2011,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,96.8
2012,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,97.6
2013,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,96.3
2014,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,96.0
2015,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,97.0
2016,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,97.5
2017,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,91.8
2018,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,92.5
2019,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,91.652622
2020,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,89.92219
2021,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,909.0
2007,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),95.0
2008,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),94.9
2009,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),95.5
2010,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),96.8
2011,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),96.4
2012,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),97.2
2013,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),96.6
2014,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),93.7
2015,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),94.0
2016,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),90.5
2017,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),86.5
2018,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),90.3
2019,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),92.018905
2020,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),73.377391
2021,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),811.0
2007,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),95.2
2008,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),96.7
2009,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),95.4
2010,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),95.7
2011,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),95.2
2012,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),98.5
2013,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),99.2
2014,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),96.0
2015,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),97.6
2016,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),96.7
2017,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),98.0
2018,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),95.2
2019,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),95.586032
2020,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),87.340379
2021,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),851.0
2007,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),,98.8
2008,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),,99.1
2009,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),,98.9
2010,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),,98.3
2011,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),,97.2
2012,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),,97.7
2013,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),,98.666102
2014,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),,95.6
2015,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),,99.1
2016,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),,97.0
2017,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),,94.7
2018,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),,96.244215
2019,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),,97.245414
2020,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),,93.789319
2021,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),,934.0
2007,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,99.2
2008,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,99.0
2009,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,99.9
2010,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,97.2
2011,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,95.7
2012,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,100.0
2013,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,99.9
2014,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,98.9
2015,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,97.6
2016,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,99.9
2017,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,98.7
2018,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,92.454654
2019,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,98.254513
2020,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,98.728939
2021,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,931.0
2007,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,97.8
2008,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,99.2
2009,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,98.3
2010,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,98.3
2011,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,100.0
2012,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,99.0
2013,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,99.6
2014,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,91.7
2015,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,100.0
2016,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,95.7
2017,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,88.8
2018,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,93.49863
2019,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,93.035179
2020,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,91.334273
2021,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,948.0
2007,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,99.0
2008,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,99.7
2009,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,99.7
2010,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,99.2
2011,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,96.9
2012,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,95.7
2013,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,97.4
2014,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,95.6
2015,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,98.9
2016,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,97.7
2017,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,95.1
2018,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,96.51199
2019,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,97.67698
2020,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,96.09807
2021,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,1005.0
2007,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,99.4
2008,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,99.1
2009,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,98.9
2010,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,99.5
2011,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,96.7
2012,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,97.6
2013,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,97.3
2014,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,97.7
2015,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,98.1
2016,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,98.1
2017,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,97.0
2018,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,97.646444
2019,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,98.140747
2020,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,96.233184
2021,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,1003.0
2007,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,98.9
2008,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,99.5
2009,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,99.8
2010,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,99.7
2011,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,94.7
2012,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,96.6
2013,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,97.9
2014,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,96.1
2015,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,99.0
2016,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,99.2
2017,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,96.8
2018,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,98.10916
2019,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,99.619945
2020,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,97.454999
2021,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,938.0
2007,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,98.6
2008,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,99.2
2009,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,97.6
2010,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,97.1
2011,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,97.7
2012,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,98.8
2013,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,97.7
2014,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,94.3
2015,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,97.1
2016,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,97.0
2017,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,95.6
2018,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,98.413291
2019,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,95.974889
2020,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,95.177033
2021,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,954.0
2007,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,99.1
2008,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,97.4
2009,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,98.7
2010,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,96.4
2011,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,97.1
2012,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,96.4
2013,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,99.3
2014,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,96.5
2015,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,98.6
2016,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,95.0
2017,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,96.3
2018,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,97.43813
2019,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,99.450649
2020,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,97.514722
2021,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,923.0
2007,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),99.8
2008,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),99.9
2009,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),98.6
2010,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),99.0
2011,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),97.4
2012,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),97.7
2013,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),98.4
2014,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),95.6
2015,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),99.8
2016,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),95.1
2017,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),91.7
2018,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),96.281062
2019,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),96.444387
2020,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),83.697508
2021,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),893.0
2007,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),98.8
2008,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),98.9
2009,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),98.2
2010,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),97.4
2011,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),99.7
2012,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),98.1
2013,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),98.7
2014,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),99.9
2015,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),99.7
2016,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),96.8
2017,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),97.7
2018,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),99.425085
2019,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),97.981883
2020,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),93.662127
2021,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),880.0
2015,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),,96.8
2016,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),,97.2
2017,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),,94.2
2018,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),,92.0
2019,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),,95.083643
2020,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),,88.782542
2021,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),,896.0
2015,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Batken,97.3
2016,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Batken,99.3
2017,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Batken,96.3
2018,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Batken,94.6
2019,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Batken,99.597512
2020,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Batken,83.440107
2021,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Batken,892.0
2015,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Jalal-Abad,97.3
2016,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Jalal-Abad,95.9
2017,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Jalal-Abad,94.5
2018,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Jalal-Abad,93.8
2019,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Jalal-Abad,90.089857
2020,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Jalal-Abad,88.195819
2021,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Jalal-Abad,848.0
2015,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Issyk-Kul,98.2
2016,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Issyk-Kul,96.4
2017,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Issyk-Kul,96.3
2018,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Issyk-Kul,95.0
2019,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Issyk-Kul,94.992818
2020,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Issyk-Kul,88.268865
2021,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Issyk-Kul,962.0
2015,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Naryn,96.8
2016,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Naryn,96.7
2017,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Naryn,97.0
2018,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Naryn,95.1
2019,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Naryn,97.283381
2020,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Naryn,91.250904
2021,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Naryn,956.0
2015,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Osh,96.3
2016,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Osh,98.8
2017,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Osh,97.2
2018,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Osh,92.1
2019,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Osh,98.41451
2020,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Osh,95.711275
2021,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Osh,913.0
2015,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Talas,97.2
2016,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Talas,96.1
2017,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Talas,94.0
2018,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Talas,96.0
2019,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Talas,94.297841
2020,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Talas,95.762224
2021,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Talas,914.0
2015,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Chui,97.6
2016,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Chui,98.7
2017,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Chui,92.6
2018,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Chui,92.1
2019,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Chui,94.916128
2020,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Chui,90.955903
2021,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Chui,923.0
2015,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Bishkek (city),95.0
2016,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Bishkek (city),94.8
2017,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Bishkek (city),90.4
2018,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Bishkek (city),83.4
2019,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Bishkek (city),93.823491
2020,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Bishkek (city),79.378126
2021,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Bishkek (city),887.0
2015,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Osh (city),97.9
2016,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Osh (city),96.8
2017,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Osh (city),90.0
2018,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Osh (city),93.9
2019,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Osh (city),95.896254
2020,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Osh (city),87.352779
2021,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Osh (city),849.0
